ClinicalTrials.gg
RecruitingNCT07479992AoS-SEDAIUpdated Nov 4, 2026

Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study

An observational study in Aortic Stenosis, sponsored by Idoven 1903 S.L.. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Idoven 1903 S.L. · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.

Planned enrollment
4th of 98
5,000 · median 300
Started
2026
with 5 others
Observational
98 of 191
22 open now
Primary completion
2027-01
later than 30 of 57 live
Registered
186th of 191
by date

Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 4th largest by planned enrollment of the 98 observational ones that give a count, is one of 6 that started in 2026, is one of 98 observational ones, reaches primary completion later than 30 of the 57 other live ones, and was the 186th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Aortic Valve Stenosis with a site in Germany, or all of them as a file.
02

Study summary

AoS-SEDAI study is an observational, multicenter, retrospective and prospective clinical study.

This study aims to assess Willem Artificial Intelligence (AI) ability to distinguish between aortic stenosis (AS) and non-AS patients from 12-lead electrocardiogram (ECG) data.

Read the detailed description

Aortic Stenosis (AS) is a common and progressive valvular heart disease, especially in older adults, yet significantly underdiagnosed. Many individuals with significant AS may remain asymptomatic for extended periods or experience vague symptoms, delaying diagnosis for several years. In some cases, sudden cardiac events or decompensation may be the first indication of advanced AS, particularly in those who have not undergone regular cardiovascular evaluation.

The primary method for diagnosing AS is echocardiography, which allows visualization of valve anatomy and assessment of transvalvular gradients. However, reliance on symptom reporting or late-stage signs, that trigger a provider to order an echo, can result in missed opportunities for earlier detection. Additionally, electrocardiographic changes-such as left ventricular hypertrophy or strain patterns-can often be detected before structural abnormalities are visible on imaging studies. This delay between electrical changes evolution and later structural findings creates a valuable opportunity to intervene sooner, for example with a valve replacement. This diagnostic latency highlights a critical window where early identification through Artificial Intelligence (AI) analysis of electrocardiograms (ECGs) and timely referral to cardiology can significantly alter disease trajectory and improve outcomes, especially in primary care and community health settings.

AoS-SEDAI study is an observational, retrospective and prospective, multicenter clinical study. Even though controls will be distinguished from AS patients for ground truth and performance evaluation, this is a single-arm study since there are no differences in study interventions.

03

Conditions studied

  • Aortic Stenosis

Keywords

  • artificial intelligence
  • electrocardiogram
  • deep learning
  • cardiac disease
  • aortic stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The target population consists of patients under assessment of Aortic Stenosis (AS).

Screened patients need to have 12-lead ECG recordings within 90 days of a transthoracic echocardiogram (TTE). In the case of multiple ECGs and TTEs per patient, all of them will be selected and analysed accordingly considering the corresponding PI diagnosis at each time. In the event of a patient with a different diagnosis over time (e.g. non-AS confirmed diagnosis later on diagnosed with AS), multiple timepoint ECGs will be categorized so that the same patient is not included both in the control and in the AS populations.

Controls will include non-AS patients with relevant TTE and clinical findings during AS differential diagnosis (such as hypertensive heart disease, structural heart diseases, hypertrophic cardiomyopathy among other cardiomyopathies, mild aortic stenosis, and no significant aortic leaflet calcification).

Eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years;
  • All available 12-lead with a 10 seconds minimum length on raw data digital format will be included
  • Available clinical data corresponding to each ECG to confirm patient demographics and Aortic Stenosis diagnosis
  • Available transthoracic echocardiogram (TTE) within +/- 90 days of each ECG recording

No exclusion criteria are defined for this study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Aortic Stenosis patients

    Subjects with an Aortic Stenosis diagnosis confirmed by the physician following their routine practice (e.g. ESC Guidelines), including complete clinical assessment with echocardiogram or other complementary techniques.

    Device: Willem AI ECG assessment

  • Non-Aortic Stenosis patients (Controls)

    Subjects without Aortic Stenosis confirmed by the physician after thorough evaluation following their routine practice.

    Device: Willem AI ECG assessment

Interventions

  • DeviceWillem AI ECG assessment

    There is no study intervention. The Willem AI platform will assess all study electrocardiograms (ECGs) for the identification of aortic stenosis. Regardless of retrospective or prospective enrollment, Willem output will not be provided to the healthcare professional user for clinical evaluation, and therefore routine practice will not be impacted nor altered.

06

What researchers measure

Primary outcomes

  1. Willem performance to detect severe Aortic Stenosis

    Performance of Willem AI platform to distinguish between severe Aortic Stenosis (AS) patients with confirmed diagnosis and non-AS patients, by means of the following performance metrics: Area Under the Receiver Operating Characteristic curve (AUROC), diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The Standard Of Care (SOC) investigator diagnosis will be used as the ground truth.

    Time frame: ECG will be performed at baseline, and ECG analysis by Willem AI will be performed retrospectively throughout the trial, and finalized upon recruitment completion.

Secondary outcomes

  1. Willem performance to detect moderate Aortic Stenosis

    Performance of Willem AI platform to distinguish between moderate Aortic Stenosis (AS) patients with confirmed diagnosis and non-AS patients, by means of the following performance metrics: Area Under the Receiver Operating Characteristic curve (AUROC), diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The Standard Of Care (SOC) investigator diagnosis will be used as the ground truth.

    Time frame: ECG will be performed at baseline, and ECG analysis by Willem AI will be performed retrospectively throughout the trial, and finalized upon recruitment completion.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 9 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Jan 2027 and completion Dec 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartActual
Apr 28, 2026
Primary completionEst.
Jan 2027was Oct 2026
CompletionEst.
Feb 2027was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Jan 2027
Nov 4, 2026
Study completion
Dec 2026→Feb 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Oct 2026→Jan 2027
    Study completion Dec 2026→Feb 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07479992
Lead sponsor
Idoven 1903 S.L.
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Apr 28, 2026
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Manuel Marina-Breysse, MD, PhD
Contact
clinical@idoven.ai
+34669752391

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion